1. Home
  2. PINE vs ALLO Comparison

PINE vs ALLO Comparison

Compare PINE & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpine Income Property Trust Inc.

PINE

Alpine Income Property Trust Inc.

HOLD

Current Price

$17.52

Market Cap

232.7M

Sector

Real Estate

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.50

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PINE
ALLO
Founded
2019
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.7M
252.9M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
PINE
ALLO
Price
$17.52
$1.50
Analyst Decision
Strong Buy
Buy
Analyst Count
3
11
Target Price
$17.67
$8.67
AVG Volume (30 Days)
159.5K
2.4M
Earning Date
10-23-2025
11-06-2025
Dividend Yield
6.51%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$57,423,000.00
N/A
Revenue This Year
$14.13
N/A
Revenue Next Year
$2.05
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
14.81
N/A
52 Week Low
$13.10
$0.86
52 Week High
$17.88
$3.78

Technical Indicators

Market Signals
Indicator
PINE
ALLO
Relative Strength Index (RSI) 73.34 61.26
Support Level $17.10 $1.39
Resistance Level $17.54 $1.52
Average True Range (ATR) 0.41 0.10
MACD -0.03 0.01
Stochastic Oscillator 78.62 87.50

Price Performance

Historical Comparison
PINE
ALLO

About PINE Alpine Income Property Trust Inc.

Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: